GCGL and Frontage Sign MOU to Target the Global Clinical Trial Market

Signing of Mutual Business Agreement to Strengthen Network Capabilities

GCGL, a global clinical trial sample analysis organization, announced on the 24th that it has signed a memorandum of understanding (MOU) with Frontage Laboratories, a global contract research organization (CRO), to target the global clinical trial market.

Cho Gwan-gu, CEO of GCEL (left), and Nanjang Frontage Senior Vice President attended the business agreement signing ceremony held at the GCEL headquarters in Yongin, Gyeonggi Province on the 23rd and took a commemorative photo. GCEL

This agreement was established to combine the clinical trial services and global networks of both companies, aiming to strengthen their competitiveness in the United States and Asia-Pacific (APAC) regions and to promote mutual growth.

At the signing ceremony held at GCGL headquarters in Yongin, Gyeonggi Province, on the 23rd, the two companies confirmed their commitment to cooperation and discussed various areas of collaboration, including clinical trial service cooperation in the United States and APAC markets, joint marketing and project support, and the creation of new business opportunities.

Through this agreement, both companies plan to jointly conduct global clinical trial projects based on their respective expertise and networks accumulated in their regions. They will also provide global clients with prompt and differentiated integrated services. In particular, GCGL aims to strengthen its global clinical trial analysis capabilities and networks in the United States and China, while Frontage Laboratories is expected to establish an efficient clinical trial support system in the APAC market.

Cho Gwan-gu, CEO of GCGL, stated, "Our strategic partnership with Frontage Laboratories goes beyond simple collaboration. By combining GCGL's clinical trial analysis expertise in the APAC region with Frontage Laboratories' global development capabilities, this will serve as an opportunity to create new growth prospects in the global clinical trial market. We will set a new standard for global clinical trial execution and deliver tangible analytical results to our clients."

Meanwhile, Frontage Laboratories is a global CRO headquartered in Pennsylvania, United States, operating 25 sites worldwide, including in the United States, Europe, and China. It provides integrated product development services from drug discovery to late-stage clinical trials. Its main services include drug metabolism and pharmacokinetics (DMPK), sample analysis and formulation development, preclinical and clinical material manufacturing, bioanalysis, preclinical safety and toxicity assessment, and early-phase clinical trials.

This content was produced with the assistance of AI translation services.